Pharmaceutical Companies

Insilico Medicine leverages AI to dramatically accelerate drug candidate development, reducing timelines to around a year, with a record nine months for early discovery. Their generative AI identifies targets and designs molecules, leading to a refined pipeline and faster preclinical nomination. While AI expedites early stages, subsequent clinical trials, manufacturing, and regulatory reviews remain distinct phases. The company has generated 31 preclinical candidates and 13 IND clearances.